-The Times of India MUMBAI: Instead of simplifying the process for organ donation, the Centre seems to be imposing more bureaucratic hurdles and adding to the trauma of donors' family members. A draft of fresh national guidelines for organ transplant says forensic departments of government hospitals will play a pivotal role in organ donation. The problem, say experts, is that grieving relatives may have to wait longer-first, for busy, overworked forensic experts...

-The Times of India MUMBAI: It's widely known that a month's dose of cancer drugs can cost lakhs, but what isn't common knowledge is that Tata Memorial Hospital's Doctors are working on alternatives that could cost less than Rs 1,000 a month. Dubbed the metronomic treatment protocol, it comprises daily consumption of a combination of low-dose medicines that are cheap because they have been around for decades. "There is no need to...

-The Telegraph The Union health ministry has signalled its intentions to go ahead with plans to introduce a cadre of rural health care providers through a new BSc course, ignoring objections from a parliamentary panel. The ministry told Delhi High Court this week that it had sent a draft cabinet note on the three-and-a-half-year course in community health to the Prime Minister's Office for comments. This is standard procedure before the matter...

-The Business Standard Govt should streamline its free medicines plan The Centre is reportedly going to shelve a plan to procure generic drugs for free supply to patients throughout the country. This is a serious error. Reportedly, states will instead be asked to do so; but, if a perceived inability to procure, stock and distribute these drugs is the reason for backtracking on the plan, how precisely will states be free of...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...